NEW YORK (GenomeWeb News) – Agilent Technologies has signed a co-marketing agreement with Life Technologies related to targeted resequencing, an Agilent official said today.

Speaking at the UBS Global Life Sciences Conference, Nick Roelofs, president of Agilent's Life Sciences Group, said that the company has signed an agreement with Life Technologies to co-market Agilent's SureSelect Target Enrichment System with the Applied Biosystems SOLiD sequencing system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.